1st Global Advisors’s AstraZeneca AZN Stock Holding History

1st Global Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-3,706	Closed	-$202K	–	507
2016 Q4	$202K	Sell	3,706 -1,526	-29%	-$86.6K	0.03%	491
2016 Q3	$344K	Buy	+5,232	New	+$342K	0.05%	334
2015 Q2	–	Sell	-3,201	Closed	-$219K	–	464
2015 Q1	$219K	Buy	+3,201	New	+$222K	0.03%	417

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

1st Global Advisors's AZN Position: Q1 2017 in Review

1st Global Advisors sold out of AstraZeneca (AZN) in Q1 2017, closing a stake of 3,706 shares — an estimated $202K sold.

1st Global Advisors first reported a position in AZN in Q1 2015 and held it in 3 quarters. The position peaked at $344K in Q3 2016. 460 funds tracked by Wall St. Rank hold AZN as of Q1 2017.

1st Global Advisors reported no remaining AstraZeneca position as of Q1 2017 after selling out during the quarter.
1st Global Advisors sold 3,706 AstraZeneca shares in Q1 2017, an estimated $202K.
1st Global Advisors first reported a position in AstraZeneca in Q1 2015 and held it in 3 quarters.
1st Global Advisors's AstraZeneca position peaked at $344K in Q3 2016.
460 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2017.

Based on 1st Global Advisors's 13F filing for Q1 2017, filed 9 May 2017.